LSP (Life Sciences Partners), the leading life sciences investor in Europe, has recently announced that it has held its final close of LSP 6 at the $600 million (approx €530 million) hard cap. To date, this has been the largest fund ever raised in Europe focused on life sciences ventures.
With this funding, LSP currently has $1.1 billion (approx €965 million) of capital to invest across LSP 6, the LSP Health Economics Fund, and LSP’s public fund and mandates. Since 1988, LSP’s management has raised $2.5 billion (approx €2.2 billion) since it started to invest in the life sciences in 1988. The group has offices in Amsterdam, Munich, and Boston.
Attracted capital from diverse investor base!
Based out of Amsterdam, the company attracted capital from a diverse investor base, including pension funds, insurance companies, wealth managers, government funds and family offices. Most notably, the Dutch investment firm has commitments from Bristol Myers Squibb and Otsuka Pharmaceutical, validating LSP’s pivotal market position.
Companies developing new medical technologies!
For the uninitiated, LSP 6 will invest in 15-18, predominantly European private companies developing new medications or medical technologies, who turn cutting-edge scientific innovations into real-world healthcare solutions.